Narrow use codes can also lead to failures by generic drug companies to carve-out critical label information.
January 03, 2022
Drug maker’s decision to list auto-injector patent was not unreasonable when FDA had declined to answer seven industry letters asking whether a drug delivery device patent could be listed in Orange Book.
January 23, 2018
New York / Tokyo
+1 212.652.0787 / +81 80 3515 5230
Subscribe to our blog: